Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more
Arcticzymes Technologies ASA - Asset Resilience Ratio
Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 21.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0% |
| Short-term Investments | Nkr76.94 Million | 21.29% |
| Total Liquid Assets | Nkr76.94 Million | 21.29% |
Asset Resilience Insights
- Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 21.29% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio
Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Arcticzymes Technologies ASA (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.29% | Nkr76.94 Million | Nkr361.41 Million | -49.57pp |
| 2024-12-31 | 70.86% | Nkr243.94 Million | Nkr344.26 Million | +17.55pp |
| 2023-12-31 | 53.31% | Nkr180.89 Million | Nkr339.32 Million | -23.22pp |
| 2022-12-31 | 76.53% | Nkr244.16 Million | Nkr319.04 Million | +5.99pp |
| 2021-12-31 | 70.54% | Nkr200.42 Million | Nkr284.11 Million | +7.38pp |
| 2020-12-31 | 63.17% | Nkr140.18 Million | Nkr221.91 Million | +22.85pp |
| 2019-12-31 | 40.32% | Nkr31.29 Million | Nkr77.61 Million | -6.24pp |
| 2018-12-31 | 46.55% | Nkr31.66 Million | Nkr68.02 Million | -3.05pp |
| 2017-12-31 | 49.60% | Nkr30.59 Million | Nkr61.68 Million | -17.60pp |
| 2016-12-31 | 67.19% | Nkr57.67 Million | Nkr85.83 Million | -- |